Heart Failure & Obesity Study

Living with obesity or overweight alongside type 2 diabetes significantly increases the risk of serious cardiovascular events, including heart attack, stroke, and heart failure. Despite the range of treatments available, many people find it difficult to achieve meaningful, sustained improvements across all three of these interconnected conditions at the same time.

This study is evaluating a once-weekly injectable medication designed to target both weight management and cardiometabolic outcomes. It is specifically for people who have both type 2 diabetes and at least one additional cardiovascular risk factor such as coronary heart disease, prior heart attack or stroke, peripheral arterial disease, or chronic kidney disease.

This trial is not yet open for enrollment. Register your interest now and our team will contact you as soon as it opens, registering early means you may be among the first to be assessed and could save waiting time when the study begins.

• Type 2 diabetes diagnosed for at least 6 months, with HbA1c between 6.5% and 9.5%
• Overweight or obese (BMI of 25 or above)
• At least one cardiovascular risk factor — such as coronary heart disease, prior heart attack or stroke, peripheral arterial disease, or chronic kidney disease
• On stable diabetes medications for at least 3 months

Not sure if you qualify? Register your interest and our team will contact you when enrolment opens to discuss your eligibility — no commitment required.

• Once the study opens, you will be invited for a screening visit including fasting blood tests, ECG, and a general health assessment
• If eligible, you will be randomly assigned to the investigational once-weekly injection or a placebo
• More frequent visits in the early phase - every 4 weeks and reducing to every 12 weeks after the initial period
• Regular fasting blood tests, weight checks, and wellbeing questionnaires at each visit
• All study medications, tests, and consultations provided at no cost
• Reimbursement for your time and reasonable travel costs at each visi

Be first in line: Registering now means you'll be contacted as soon as the study opens at our Ipswich site.

New treatment option: Access an investigational treatment targeting both weight and cardiovascular risk, at no cost.

Reimbursement: All clinic visits are reimbursed for your time and reasonable travel costs.

No commitment yet: Registering is simply an expression of interest — no obligation to participate.

Footer note: Your privacy is important. All personal information will be kept strictly confidential.

Footer note: Your privacy is important. All personal information will be kept strictly confidential.

This study is opening soon at our Ipswich and East Brisbane sites. To register your interest:

• Visit www.lcr.health and complete the online expression of interest form
• Call our team directly on (07) 3180 8045
• Email us at paul@lcr.health

Once you register, a member of our clinical team will contact you to discuss the study in more detail, answer any questions, and confirm whether you may be eligible for a screening visit.